4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $310,752 | -28.9% | 24,411 | +1.0% | 0.00% | – |
| Q2 2023 | $436,860 | +259.6% | 24,176 | +242.0% | 0.00% | – |
| Q1 2023 | $121,499 | +92.2% | 7,068 | +148.3% | 0.00% | – |
| Q4 2022 | $63,210 | -15.7% | 2,846 | -69.7% | 0.00% | – |
| Q3 2022 | $75,000 | +13.6% | 9,387 | 0.0% | 0.00% | – |
| Q2 2022 | $66,000 | -47.2% | 9,387 | +13.9% | 0.00% | – |
| Q1 2022 | $125,000 | -30.9% | 8,240 | 0.0% | 0.00% | – |
| Q4 2021 | $181,000 | +21.5% | 8,240 | +49.7% | 0.00% | – |
| Q3 2021 | $149,000 | +645.0% | 5,505 | +576.3% | 0.00% | – |
| Q2 2021 | $20,000 | -41.2% | 814 | +2.8% | 0.00% | – |
| Q1 2021 | $34,000 | – | 792 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |